Polifarma demonstrated its strength once again

0
110

Contributing to public health and the health sector in Turkey for 36 years, with 100% domestic capital, Polifarma has not only been among Turkey’s “Companies with the Highest R&D Expenditure”, it also took its place in the top 10 among “Companies Carrying out the Most Projects in R&D Centers”.

 

The results of the ‘R&D 250, Turkey’s Top R&D Spending Companies’ Survey, which was conducted for the 9th time this year by the economy and business portal Turkishtime, have been announced. With 100% Turkish capital and exporting to 70 countries, Polifarma has risen 39 places compared to the previous year and ranked 182nd among the 250 Companies with the Highest R&D Expenditures* in all sectors, according to Turkey’s 2021 Data.

Ranked 10th among the “Companies Carrying out the Most Projects in R&D Centers” in all sectors, Polifarma once again demonstrated its strength in R&D with this research. In addition, it was ranked 44th in the “Number of Women Working in R&D Centers” and ranked in the top 50.

“This success in R&D is the fruit of our 15-year strategic plan”
Pointing out that they are carrying out product development activities under the umbrella of PolR&D, which will be a first not only in Turkey but also in the world, Vildan Kumrulu, Vice Chairman of Polifarma Pharmaceuticals, said, “In order to realize innovations for health needs. In this context, we continue to improve ourselves day by day. While undertaking this important role in the field of health, it is not a coincidence that we are in the 10th rank today in the “Companies Carrying out the Most Projects in R&D Centers” in Turkey; This success is the fruit of our 15-year strategic plan, the result of our R&D investments, which we have built from product selection to human resources and put effort into it.

“We have the technical knowledge to develop all kinds of pharmaceutical forms in our PolR&D center”
Ömer Faruk Fırat, Pharmaceutical R&D and Business Development Director at Polifarma, underlined that the focus of all R&D studies is to contribute to health, he said, “We have the technical knowledge to develop all kinds of pharmaceutical forms in our PolR&D center. We are about to reach a conclusion in our molecule, which we carry out synthesis studies on the basis of mRNA technology. In addition, we have completed our synthesis studies on a molecule in the category of rare diseases. In this project, we got very close to exporting the drug abroad by synthesizing the raw material and turning it into a drug. With this project, we are happy that we contribute to the access of thousands of patients every year in Turkey without waiting for them to come from abroad.”